Overview

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to further evaluate the long-term safety and tolerability profiles of BG00002 (natalizumab) in Japanese participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objective of this study is to further evaluate the long-term efficacy profile of BG00002 in Japanese participants with RRMS.

Phase:

Phase 2

Details

Lead Sponsor:

Biogen

Treatments:

Natalizumab